相似文献
1
Neuroblastoma: developmental biology, cancer genomics and immunotherapy.
Nat Rev Cancer. 2013 Jun;13(6):397-411. doi: 10.1038/nrc3526.
2
New insights into the genetics of neuroblastoma.
Mol Diagn Ther. 2013 Apr;17(2):63-9. doi: 10.1007/s40291-013-0019-6.
3
Neuroblastoma progress on many fronts: the Neuroblastoma Research Symposium.
Pediatr Blood Cancer. 2012 Apr;58(4):649-51. doi: 10.1002/pbc.23329. Epub 2011 Sep 15.
4
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Oncogene. 2012 Nov 15;31(46):4859-67. doi: 10.1038/onc.2011.647. Epub 2012 Jan 23.
5
The ALK receptor in sympathetic neuron development and neuroblastoma.
Cell Tissue Res. 2018 May;372(2):325-337. doi: 10.1007/s00441-017-2784-8. Epub 2018 Jan 27.
6
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.
7
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Oncogene. 2013 Feb 21;32(8):1059-65. doi: 10.1038/onc.2012.106. Epub 2012 Apr 9.
8
Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Cancer Lett. 2012 Apr 1;317(1):72-7. doi: 10.1016/j.canlet.2011.11.013. Epub 2011 Nov 13.
9
Targeting anaplastic lymphoma kinase in neuroblastoma.
APMIS. 2019 May;127(5):288-302. doi: 10.1111/apm.12940. Epub 2019 Apr 3.
10
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Cancer Cell. 2012 Mar 20;21(3):362-73. doi: 10.1016/j.ccr.2012.02.010.
引用本文的文献
1
PLK4 as a Key Regulator of Neuroblastoma Differentiation and a Promising Therapeutic Target.
Int J Biol Sci. 2025 Jul 28;21(11):4979-4996. doi: 10.7150/ijbs.111449. eCollection 2025.
2
Microbiome in Neuroblastoma: A Virgin Island in the World of Onco-Microbiome.
Cells. 2025 Aug 7;14(15):1218. doi: 10.3390/cells14151218.
3
Integrative single-cell and bulk transcriptomic analyses identify a robust four-gene signature for risk stratification in neuroblastoma.
Transl Cancer Res. 2025 Jul 30;14(7):3920-3929. doi: 10.21037/tcr-2025-569. Epub 2025 Jul 4.
4
[F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.
Eur J Nucl Med Mol Imaging. 2025 Jul 28. doi: 10.1007/s00259-025-07449-y.
5
Clinical Significance of Promoter Mutations in Neuroblastoma.
JCO Precis Oncol. 2025 Jul;9:e2500074. doi: 10.1200/PO-25-00074. Epub 2025 Jul 10.
6
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.
Clin Cancer Res. 2025 Sep 2;31(17):3692-3701. doi: 10.1158/1078-0432.CCR-25-0180.
7
Integrated bulk and single-cell RNA sequencing reveals a cuproptosis-related LncRNA prognostic signature in neuroblastoma.
BMC Cancer. 2025 Jul 1;25(1):1076. doi: 10.1186/s12885-025-14463-8.
8
Amniotic membrane promotes doxorubicin potency by suppressing SH-SY5Y neuroblastoma cell angiogenesis.
BMC Cancer. 2025 Jun 19;25(1):1021. doi: 10.1186/s12885-025-14442-z.
9
Quantitative Proteomics Unveils the Synergistic Effects of Combination Drugs on Cytoskeleton Composition and Autophagy-Mediated Cell Death in Neuroblastoma.
J Proteome Res. 2025 Jul 4;24(7):3578-3596. doi: 10.1021/acs.jproteome.5c00191. Epub 2025 Jun 17.
10
An unusual case of neuroblastoma presenting with prolonged watery diarrhea in a pediatric patient.
Biochem Med (Zagreb). 2025 Jun 15;35(2):020901. doi: 10.11613/BM.2025.020901.
本文引用的文献
1
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.
2
The genetic landscape of high-risk neuroblastoma.
Nat Genet. 2013 Mar;45(3):279-84. doi: 10.1038/ng.2529. Epub 2013 Jan 20.
3
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat Genet. 2013 Jan;45(1):12-7. doi: 10.1038/ng.2493. Epub 2012 Dec 2.
4
Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
PLoS One. 2012;7(11):e50062. doi: 10.1371/journal.pone.0050062. Epub 2012 Nov 20.
5
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.
Front Oncol. 2012 Oct 12;2:141. doi: 10.3389/fonc.2012.00141. eCollection 2012.
6
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.
Nat Genet. 2012 Nov;44(11):1199-206. doi: 10.1038/ng.2436. Epub 2012 Oct 7.
7
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
Nat Genet. 2012 Oct;44(10):1126-30. doi: 10.1038/ng.2387. Epub 2012 Sep 2.
8
Can the exome and the immunome converge on the design of efficient cancer vaccines?
Oncoimmunology. 2012 Aug 1;1(5):579-580. doi: 10.4161/onci.20730.
9
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
J Clin Oncol. 2012 Oct 1;30(28):3525-32. doi: 10.1200/JCO.2011.40.9169. Epub 2012 Aug 27.
10
Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression.
J Clin Invest. 2012 Sep;122(9):3145-58. doi: 10.1172/JCI63401. Epub 2012 Aug 27.
Zotero 插件